This inventor holds 3 USPTO granted patents and 1 published patent application. Top assignee: Wisconsin Alumni Research Foundation. Active years: 2019-2023.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2019-2023
Title: Wei Xu: Innovator in Therapeutic Peptides and Nanoparticles
Introduction
Wei Xu is a prominent inventor based in Middleton, WI (US). He has made significant contributions to the field of biomedical research, particularly in the development of therapeutic cationic peptides and unimolecular nanoparticles. With a total of 3 patents, his work focuses on innovative solutions for cancer treatment.
Latest Patents
Wei Xu's latest patents include groundbreaking research on therapeutic cationic peptides and unimolecular nanoparticles for efficient delivery. These patents describe peptides that comprise an amino acid sequence with at least about 85% sequence identity to RYRPRAPIIAVT (SEQ ID NO: 1). The cationic peptides developed by Xu inhibit PKM2 methylation and have potential applications in treating breast cancer and other diseases characterized by PKM2 overexpression. The delivery of these PKM2 peptides to cancer cells is facilitated by pH-sensitive unimolecular nanoparticles made from anionic polymers.
Career Highlights
Wei Xu is affiliated with the Wisconsin Alumni Research Foundation, where he continues to advance his research and innovation in therapeutic applications. His work has garnered attention for its potential impact on cancer treatment methodologies.
Collaborations
Wei Xu collaborates with notable colleagues, including Shaoqin Gong and Yuyuan Wang, contributing to a dynamic research environment that fosters innovation and discovery.
Conclusion
Wei Xu's contributions to the field of therapeutic peptides and nanoparticles exemplify the innovative spirit of modern biomedical research. His work holds promise for improving treatment options for cancer patients and advancing the understanding of disease mechanisms.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile